The proton pump inhibitors market involves drugs that block acid production in the stomach. Proton pump inhibitors are extensively used for treating acid reflux, ulcers, and heartburn. They work by reducing the amount of acid secreted by gastric parietal cells in the stomach lining. Some key benefits of proton pump inhibitors include effective relief from acid reflux symptoms, healing of ulcers, and prevention of further injury to the esophagus. The growing prevalence of gastrointestinal problems such as acid reflux disease, peptic ulcers, and dyspepsia has substantially increased demand for proton pump inhibitors worldwide.
The Global Proton Pump Inhibitors Market is estimated to be valued at US$ 3.8 Mn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the proton pump inhibitors market are Horizon Therapeutics plc, Ammonett Pharma LLC, Medison Pharma Ltd., Modern Dietetics Inc., Synageva BioPharma Corp., Medison Pharma Ltd., Swedish Orphan Biovitrum AB (Sobi), Entera Health, Inc., Dipharma Francis S.r.l., Ucyclyd Pharma, Inc. Proton pump inhibitors offered by these players are widely used for treating acid-peptic disorders. The growing prevalence of gastrointestinal issues such as acid reflux, peptic ulcer disease, and dyspepsia has boosted the demand for proton pump inhibitors. As per studies, over 25 million Americans suffer from gastroesophageal reflux disease (GERD) each year. Moreover, the increasing consumption of alcohol and spicy foods is aggravating acid reflux symptoms, thereby fueling the need for effective drugs. Technological advancements have led to the development of novel delivery systems for Proton Pump Inhibitors Market Demand inhibitors such as orally disintegrating tablets and capsules. These new formulations offer distinct advantages like rapid dissolution, enhanced bioavailability, and patient adherence over conventional tablets. This is further supporting revenue growth of the global proton pump inhibitors market. Market Trends Increasing availability of generic versions: Expiry of patents for major proton pump inhibitor drugs has encouraged many generic manufacturers to launch affordable biosimilar versions. This, in turn, has made proton pump inhibitors more accessible to patients globally. Growing preference for functional foods: There is surging demand for natural remedies and functional foods for gut health and acid reflux management. Fermented foods, prebiotics, and probiotics are rising as viable alternatives to proton pump inhibitors. This trend could hamper market growth to some extent over the forecast period. Market Opportunities Pediatric applications: Proton pump inhibitors are increasingly being explored for treatment of gastrointestinal issues in infants and children. Successful pediatric clinical trials could unveil new expansion opportunities. Emerging markets: Developing economies in Asia Pacific and Latin America with growing acid reflux patient pools present lucrative business opportunities. However, affordability remains a major concern. Impact of COVID-19 on Proton Pump Inhibitors Market Growth The COVID-19 pandemic has significantly impacted the growth of the proton pump inhibitors market. During the initial phases of the pandemic, the market witnessed decline as patients avoided visiting hospitals and clinics for routine checkups and treatments due to the risk of contracting the virus. However, with the rising number of COVID-19 cases, the demand and consumption of proton pump inhibitors increased significantly. This was due to the fact that majority of COVID-19 patients required proton pump inhibitors to treat issues like stress ulcers and gastric issues arising due to coronavirus infection and its treatment. In the pre-COVID era, the market was growing steadily, supported by the increasing prevalence of acid reflux diseases, rising geriatric population and changing lifestyles. However, during the pandemic, supply chain disruptions affected the availability of raw materials and finished drugs. This led to short term decline in the market. Nevertheless, with rapid vaccination drives and development of effective treatment protocols, the market is recovering steadily. In the post-pandemic future, initiatives focusing on increasing awareness about gastrointestinal diseases and their management are expected to boost the consumption of proton pump inhibitors. In terms of geography, North America region accounts for the largest value share in the proton pump inhibitors market. This is attributed to the growing acid reflux disease burden, developed healthcare infrastructure and relatively higher spending on healthcare. The Asia Pacific region, on the other hand, represents the fastest growing regional market due to rising geriatric population, growing access to healthcare facilities and increasing awareness about acid reflux disease management. Get more insights, On Proton Pump Inhibitors Market
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
February 2024
Categories
All
|